Why the study?
Activation of PPARγ improves mechanisms underlying pulmonary arterial hypertension, but reports on potential adverse effects of thiazolidinediones reduced clinical use over the past decade.
Do PPARγ agonists improve the pathobiological mechanisms of pulmonary arterial hypertension?
Design
Review
Authors
Loading...
PPARγ activation may mitigate PAH mechanisms; leaves open clinical efficacy pending targeted trials.
Do PPARγ agonists improve the pathobiological mechanisms of pulmonary arterial hypertension?
Pharmacological activation of PPARγ with agents like pioglitazone improves multiple pathobiological mechanisms of PAH, suggesting a potential revival for their clinical use.
Kökény et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: